Dr. Rubin hosted four episodes of MedEd Talks Gastroenterology’s Pearls from the Pros on IBD Management, featuring several colleagues to discuss best practices in using different classes of IBD therapies. Dr. Rubin spoke with Dr. Bruce Sands, Gastroenterologist and Professor of Medicine at Mount Sinai, about best practices in anti-IL-12/23 therapies. With Dr. Millie Long, Associate Professor in the Department of Medicine, Division of Gastroenterology and Hepatology at University of North Carolina at Chapel Hill, Dr. Rubin discussed JAK inhibitors and their role in clinical practice. Dr. Stephen Hanauer, Professor of Medicine in Gastroenterology and Hepatology at Northwestern University, shared his expertise on Anti-TNF therapy. Finally, Dr. Rubin talked about small-molecule therapies, including S1P receptor modulation and anti-integrin therapies, with Dr. Maria T. Abreu, Professor of Medicine and Director of the Crohn’s and Colitis Center at the University of Miami.
Watch David T. Rubin accept the 2020 Sherman Prize, which is awarded to IBD clinicians, surgeons, researchers and/or academics with extraordinary track records of achievement, making exceptional and pioneering contributions that transform IBD care.
Originally presented at the Crohn’s and Colitis Congress with colleagues Fabio Cominelli, MD, PhD, of Case Western Reserve University, and Siddharth Singh, MD, of the University of California San Diego, Rubin highlighted the importance of choosing the most appropriate journal, sending pre-submission inquiries, creating a compelling cover letter and more.
To watch the complete video, click here
Click here to listen to the full interview.
Dr. David T. Rubin Summarizes His Presentation from the Advances in Inflammatory Bowel Diseases Conference on Preparing for IBD Care in the Next Pandemic
Click here for the full video of Dr. Rubin detailing his 8-point strategy for steps the gastroenterology community should take to prepare for another pandemic in the future to ensure the best outcomes for patients and conditions for professionals.
A newly discovered vascular brain barrier that blocks the passage of inflammatory molecules triggered by gut bacteria may be why patients with inflammatory bowel disease (IBD) are at increased risk for certain mental health disorders, including anxiety and depression, early research suggests.
Dr. David T. Rubin Reviews His Presentation from the American College of Gastroenterology Scientific Meeting on Therapeutic Drug Monitoring in IBD
Click here for the full video of Dr. Rubin reviewing his presentation from the American College of Gastroenterology Scientific Meeting on therapeutic drug monitoring (TDM), including the appropriate application of proactive TDM in the treatment of inflammatory bowel disease.
“The findings did not surprise us, but supported our hypothesis that patients with UC have reduced compliance of their rectum, even when they are in remission,” Dr. Rubin told Reuters Health by email. “The exciting new finding is that those who normalized their histology – i.e., biopsies show no evidence of chronic colitis – had compliance similar to the non-colitis control group.”
Click here to listen to Dr. Rubin speak with colleagues and IBD Drive Time hosts Raymond Cross, MD and Millie Long, MD on using newly-approved ozanimod in treating ulcerative colitis.